Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

Video

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

There are 2 CAR T-cell products that are commercially available now, says Shaughnessy: axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah). These products are available for adults with relapsed/refractory diffuse large B-cell lymphoma who have failed all standard therapies. There has been a gap in the availability of treatment for these patients.

CAR T-cell therapies now provide very meaningful responses in these patients, some of which have been very durable for a number of months, or even years. CAR T-cell therapies are very important in filling this gap in patients with relapsed/refractory lymphoma, as well as in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Once again, there is no standard therapy for this population, though CAR T-cell therapy is offering durable remissions in a percentage of these patients, concludes Shaughnessy.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.